Advertisement

Diabetologia

, Volume 58, Issue 2, pp 334–345 | Cite as

Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant

  • Jeffrey J. GaynorEmail author
  • Gaetano Ciancio
  • Giselle Guerra
  • Junichiro Sageshima
  • Lois Hanson
  • David Roth
  • Michael J. Goldstein
  • Linda Chen
  • Warren Kupin
  • Adela Mattiazzi
  • Lissett Tueros
  • Sandra Flores
  • Luis J. Barba
  • Adrian Lopez
  • Jose Rivas
  • Phillip Ruiz
  • Rodrigo Vianna
  • George W. BurkeIII
Article

Abstract

Aims/hypothesis

To better understand the implications of new-onset diabetes after transplant (NODAT), we used our prospectively followed cohort of 628 adult primary kidney transplant recipients to determine the prognostic impact of pretransplant diabetes and NODAT.

Methods

The study cohort consisted of all participants in four randomised immunosuppression trials performed at our centre since May 2000. For each cause-specific hazard analysed, Cox stepwise regression was used to determine a multivariable model of significant baseline predictors; the multivariable influence of having pretransplant diabetes and NODAT (t) (the latter defined as a zero-one, time-dependent covariate) was subsequently tested. Similar analyses of estimated glomerular filtration rate (eGFR) at 36 and 60 months post transplant were performed using stepwise linear regression. Finally, a repeated measures analysis of mean HbA1c as a function of diabetes category (pretransplant diabetes vs NODAT) and randomised trial (first to fourth) was performed.

Results

Median follow-up was 56 months post transplant. Patients with pretransplant diabetes comprised 23.4% (147/628), and 22.5% (108/481) of the remaining patients developed NODAT. Pretransplant diabetes had no prognostic influence on first biopsy-proven acute rejection and death-censored graft failure hazard rates, nor on eGFR, but was associated with significantly higher rates of death with a functioning graft (DWFG) (p = 0.003), DWFG due to a cardiovascular event (p = 0.005) and infection that required hospitalisation (p = 0.03). NODAT (t) had no unfavourable impact on any of these hazard rates nor on eGFR, with actuarial freedom from DWFG remaining at over 90% among patients in pre- and post-NODAT states at 72 months post transplant/NODAT. Mean HbA1c for patients in the first to fourth randomised trials, averaged across diabetes category, decreased by trial (7.28%, 6.92%, 6.87% and 6.64% [56.1, 52.1, 51.6 and 49.1 mmol/mol], respectively; p = 0.02).

Conclusions/interpretation

Less-than-expected post-NODAT risk for graft loss and death may exist in the current climate of tighter glucose monitoring post transplant.

Keywords

Kidney transplantation New-onset diabetes after transplant Pretransplant diabetes mellitus Prognostic impact 

Abbreviations

BPAR

Biopsy-proven acute rejection

CAD

Coronary artery disease

DGF

Delayed graft function

DWFG

Death with a functioning graft

DWFG-CV

DWFG due to a cardiovascular event

eGFR

Estimated glomerular filtration rate

MMF

Mycophenolate mofetil

NODAT

New-onset diabetes after transplant

Notes

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement

All of the co-authors contributed to each of the following: (1) substantial contribution to conception and design, acquisition of data and/or analysis and interpretation of data; (2) drafting the article and/or revising it critically for important intellectual content and (3) final approval of the version to be published. JJG is the guarantor of this work and accepts full responsibility for the work and/or conduct of the study, had access to the data and controlled the decision to publish.

References

  1. 1.
    Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ (1996) Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7:158–165PubMedGoogle Scholar
  2. 2.
    Cosio FG, Alamir A, Yim S et al (1998) Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int 53:767–772PubMedCrossRefGoogle Scholar
  3. 3.
    Kasiske BL, Chakkera HA, Roel J (2000) Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11:1735–1743PubMedGoogle Scholar
  4. 4.
    Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK (2000) Long-term survival in renal transplant recipients with graft function. Kidney Int 57:307–313PubMedCrossRefGoogle Scholar
  5. 5.
    Revanur VK, Jardine AG, Kingsmore DB et al (2001) Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 15:89–94PubMedCrossRefGoogle Scholar
  6. 6.
    Meier-Kriesche HU, Baliga R, Kaplan B (2003) Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 75:1291–1295PubMedCrossRefGoogle Scholar
  7. 7.
    Lentine KL, Brennan DC, Schnitzler MA (2005) Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 16:496–506PubMedCrossRefGoogle Scholar
  8. 8.
    Soveri I, Holdaas H, Jardine A, Gimpelewicz C, Staffler B, Fellstrom B (2006) Renal transplant dysfunction: importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 21:2282–2289PubMedCrossRefGoogle Scholar
  9. 9.
    Hjelmesaeth J, Hartmann A, Leivestad T et al (2006) The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 69:588–595PubMedCrossRefGoogle Scholar
  10. 10.
    Cosio FG, Hickson LJ, Griffin MD, Stegall MD, Kudva Y (2008) Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant 8:593–599PubMedCrossRefGoogle Scholar
  11. 11.
    Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S (2010) Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) Database. Am J Kidney Dis 56:1127–1139PubMedCrossRefGoogle Scholar
  12. 12.
    Taber DJ, Meadows HB, Pilch NA et al (2013) Pre-existing diabetes significantly increases the risk of graft failure and mortality following renal transplantation. Clin Transplant 27:274–282PubMedCrossRefGoogle Scholar
  13. 13.
    Fowler MJ (2008) Microvascular and macrovascular complications of diabetes. Clin Diabetes 26:77–82CrossRefGoogle Scholar
  14. 14.
    Boudreaux JP, McHugh L, Canafax DM et al (1987) The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 44:376–381PubMedCrossRefGoogle Scholar
  15. 15.
    Cosio FG, Pesavento TE, Kim S et al (2002) Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 62:1440–1446PubMedCrossRefGoogle Scholar
  16. 16.
    Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ (2003) Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3:178–185PubMedCrossRefGoogle Scholar
  17. 17.
    Cole EH, Johnston O, Rose CL, Gill JS (2008) Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 3:814–821PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Valderhaug TG, Hjelmesaeth J, Hartmann A et al (2011) The association of early post-transplant glucose levels with long-term mortality. Diabetologia 54:1341–1349PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Ducloux D, Kazory A, Chalopin JM (2005) Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 79:438–443PubMedCrossRefGoogle Scholar
  20. 20.
    Matas AJ, Gillingham KJ, Humar A et al (2008) Posttransplant diabetes mellitus and acute rejection: impact on kidney transplant outcome. Transplantation 85:338–343PubMedCrossRefGoogle Scholar
  21. 21.
    Valderhaug TG, Hjelmesaeth J, Jenssen T et al (2012) Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. Transplantation 94:714–720PubMedCrossRefGoogle Scholar
  22. 22.
    Ciancio G, Burke GW, Gaynor JJ et al (2004) A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I Drug interactions and rejection at one year. Transplantation 77:244–251PubMedCrossRefGoogle Scholar
  23. 23.
    Ciancio G, Burke GW, Gaynor JJ et al (2004) A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 77:252–258PubMedCrossRefGoogle Scholar
  24. 24.
    Ciancio G, Burke GW, Gaynor JJ et al (2006) A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 81:845–852PubMedCrossRefGoogle Scholar
  25. 25.
    Guerra G, Ciancio G, Gaynor JJ et al (2011) Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol 22:1758–1768PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Ciancio G, Burke GW, Gaynor JJ et al (2005) A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 80:457–465PubMedCrossRefGoogle Scholar
  27. 27.
    Ciancio G, Burke GW, Gaynor JJ et al (2008) A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow up. Clin Transplant 22:200–210PubMedCrossRefGoogle Scholar
  28. 28.
    Ciancio G, Gaynor JJ, Roth D et al (2010) Randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in living donor renal transplantation. Transplant Proc 42:3503–3506PubMedCrossRefGoogle Scholar
  29. 29.
    Ciancio G, Gaynor JJ, Guerra G et al (2014) Randomized trial of three induction antibodies in kidney transplantation: long-term results. Transplantation 97:1128–1138PubMedCrossRefGoogle Scholar
  30. 30.
    Ciancio G, Burke GW, Gaynor JJ et al (2008) Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation 86:67–74PubMedCrossRefGoogle Scholar
  31. 31.
    Ciancio G, Gaynor JJ, Zarak A et al (2011) Randomized trial of mycophenolate mofetil vs. enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. Transplantation 91:1198–1205PubMedCrossRefGoogle Scholar
  32. 32.
    Ciancio G, Gaynor JJ, Sageshima J et al (2011) Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. Transplantation 92:1348–1357PubMedCrossRefGoogle Scholar
  33. 33.
    Ciancio G, Gaynor JJ, Sageshima J et al (2010) Favorable outcomes with machine perfusion and longer pump times in kidney transplantation: a single-center, observational study. Transplantation 90:882–890PubMedCrossRefGoogle Scholar
  34. 34.
    Solez K, Axelsen RA, Benediktsson H et al (1993) International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 44:411–422PubMedCrossRefGoogle Scholar
  35. 35.
    Solez K, Colvin RB, Racusen LC et al (2007) Banff ‘05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant 7:518–526PubMedCrossRefGoogle Scholar
  36. 36.
    American Diabetes Association (2011) Diagnosis and classification of diabetes mellitus. Diabetes Care 34(Suppl 1):S62–S69PubMedCentralCrossRefGoogle Scholar
  37. 37.
    The International Expert Committee (2009) International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32:1327–1334PubMedCentralCrossRefGoogle Scholar
  38. 38.
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMedCrossRefGoogle Scholar
  39. 39.
    Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570–2581PubMedCrossRefGoogle Scholar
  40. 40.
    Barbosa J, Steffes MW, Sutherland DER, Connett JE, Rao KV, Mauer SM (1994) Effect of glycemic control on early diabetic renal lesions: a 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. JAMA 272:600–606PubMedCrossRefGoogle Scholar
  41. 41.
    Weir MR, Fink JC (1999) Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 34:1–13PubMedCrossRefGoogle Scholar
  42. 42.
    Markell M (2004) New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis 43:953–965PubMedCrossRefGoogle Scholar
  43. 43.
    Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 52:17–30PubMedCrossRefGoogle Scholar
  44. 44.
    Wiesbauer F, Heinze G, Regele H et al (2010) Glucose control is associated with patient survival in diabetic patients after renal transplantation. Transplantation 89:612–619PubMedCrossRefGoogle Scholar
  45. 45.
    Guerra G, Ilahe A, Ciancio G (2012) Diabetes and kidney transplantation: past, present, and future. Curr Diabetes Rep 12:597–603CrossRefGoogle Scholar
  46. 46.
    Roth D, Gaynor JJ, Reddy KR et al (2011) Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 22:1152–1160PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Jeffrey J. Gaynor
    • 1
    Email author
  • Gaetano Ciancio
    • 1
  • Giselle Guerra
    • 2
  • Junichiro Sageshima
    • 1
  • Lois Hanson
    • 1
  • David Roth
    • 2
  • Michael J. Goldstein
    • 1
  • Linda Chen
    • 1
  • Warren Kupin
    • 2
  • Adela Mattiazzi
    • 2
  • Lissett Tueros
    • 1
  • Sandra Flores
    • 1
  • Luis J. Barba
    • 1
  • Adrian Lopez
    • 1
  • Jose Rivas
    • 1
  • Phillip Ruiz
    • 1
  • Rodrigo Vianna
    • 1
  • George W. BurkeIII
    • 1
  1. 1.Miami Transplant Institute, Department of SurgeryUniversity of Miami Miller School of MedicineMiamiUSA
  2. 2.Miami Transplant Institute, Department of MedicineUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations